These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 28024944)

  • 1. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
    Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
    Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
    Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
    Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
    World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    Tan BH; Brammer K; Randhawa N; Welch NT; Parsons SL; James EJ; Catton JA
    Eur J Surg Oncol; 2015 Mar; 41(3):333-8. PubMed ID: 25498359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
    Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia/Muscle Mass is not a Prognostic Factor for Short- and Long-Term Outcome After Esophagectomy for Cancer.
    Grotenhuis BA; Shapiro J; van Adrichem S; de Vries M; Koek M; Wijnhoven BP; van Lanschot JJ
    World J Surg; 2016 Nov; 40(11):2698-2704. PubMed ID: 27272482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of sarcopenia in patients undergoing esophagectomy for superficial esophageal squamous cell carcinoma.
    Oguma J; Ozawa S; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
    Dis Esophagus; 2019 Jul; 32(7):. PubMed ID: 30809629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.
    Barbour AP; Jones M; Gonen M; Gotley DC; Thomas J; Thomson DB; Burmeister B; Smithers BM
    Ann Surg Oncol; 2008 Oct; 15(10):2894-902. PubMed ID: 18663531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
    Zanoni A; Verlato G; Giacopuzzi S; Weindelmayer J; Casella F; Pasini F; Zhao E; de Manzoni G
    Ann Surg Oncol; 2013 Jun; 20(6):1993-9. PubMed ID: 23274533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.